Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine

Clinical Infectious Diseases

Volumn 43, Issue SUPPL. 4, 2006, Pages

  McCance Katz, Elinore F ^a,f   Moody, David E ^b   Morse, Gene D ^c   Friedland, Gerald ^d   Pade, Patricia ^a   Baker, Jennifer ^a   Alvanzo, Anika ^a   Smith, Patrick ^c   Ogundele, Abayomi ^c   Jatlow, Peter ^d   Rainey, Petrie M ^e  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d YALE UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BUPRENORPHINE; DELAVIRDINE; EFAVIRENZ; NALOXONE; NORBUPRENOPHRINE 3 GLUCURONIDE; NORBUPRENORPHINE; OPIATE AGONIST; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ALTERED MENTAL STATUS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOSE TIME EFFECT RELATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEMORY DISORDER; MENTAL DISEASE; MOTOR DYSFUNCTION; MUSCLE STIFFNESS; NIGHTMARE; OPIATE ADDICTION; PRIORITY JOURNAL; SIDE EFFECT; SLEEP DISORDER; URINARY FREQUENCY; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADULT; AREA UNDER CURVE; BUPRENORPHINE; CASE-CONTROL STUDIES; COHORT STUDIES; DELAVIRDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; OXAZINES; PROBABILITY; PROGNOSIS; REFERENCE VALUES; REVERSE TRANSCRIPTASE INHIBITORS; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 33845419520     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/508187     Document Type: Article

References (29)

1. McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis 2005; 41(Suppl 1):S89-95.
2. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://AIDSinfo.nih.gov/guidelines/. Accessed 7 May 2005.
3. Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: a review. Mt Sinai J Med 2000; 67:429-36.
4. McCance-Katz EF. Office based treatment of opioid dependence with buprenorphine. Harv Rev Psychiatry 2004; 12:321-38.
5. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigolow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55:569-80.
6. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004; 76:250-69.
7. Chang Y, Moody D, McCance-Katz E. Novel metabolites of buprenorphine in human liver microsomes and human urine. Drug Metab Dispos 2006; 34:440-8.
8. Cone E, Gorodetzky C, Yousefnejad D, Buchwald W, Johnson R. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984; 12:577-81.
9. McCance-Katz EF, Rainey P, Smith P, et al. Drug interactions between opioids and antiretroviral medications: interactions between methadone, LAAM, and delavirdine. Am J Addict 2006; 15:23-34.
10. McCance-Katz EF, Rainey P, Smith P, et al. Drug interactions between opioid and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. Am J Addict 2004; 13:163-80.
11. Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002; 72:1-9.
12. Kuhlman JJ Jr, Levine B, Johnson RE, Fudala PJ, Cone EJ. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998; 93:549-59.
13. Physicians' desk reference. 58th ed. Montvale, NJ: Thomson PDR, 2004.
14. Handlesman L, Cochrane KJ, Aronson MJ, et al. Two new rating scales for opioid withdrawal. Am J Drug Alcohol Abuse 1987; 13:293-308.
15. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-98.
16. Huang W, Moody DE, McCance-Katz EF. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography- electrospray ionization-tandem mass spectrometry. Ther Drug Monit 2006; 28:245-51.
17. Keil K, Frerichs VA, DiFrancesco R, Morse GD. Reverse phase high performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite, M8, ritonavir, and saquinavir in heparinized human plasma. Ther Drug Monit 2003; 25:340-6.
18. Shelton MJ, Hewitt RG, Adams J, Della-Coletta A, Cox S, Morse GD. Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47:1694-9.
19. McCance-Katz EF, Jatlow P, Rainey P, Friedland G. Methadone effects on zidovudine (AZT) disposition (ACTG 262). J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:435-43.
20. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
21. Iribarne C, Picart D, Dreano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 1997; 60:1953-64.
22. Bock KW. Vertebrate UDP-glucuronosyltransferases: functional and evolutionary aspects. Biochem Pharmacol 2003; 66:691-6.
23. Kuhlman JJ, Levine B, Johnson RE, et al. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998; 93:549-59.
24. Cowan A. Buprenorphine: new pharmacological aspects. Int J Clin Pract Suppl 2003; 133:3-8.
25. Dyer KR, Foster DJR, White JM, et al. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther 1999; 65:685-94.
26. Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001; 297:688-95.
27. Carrieri MP, Vlahov D, Dellamonica P, et al. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The MANIF-2000 Study Group. Drug Alcohol Depend 2000; 60:51-4.
28. Freimuth W. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Adv Exp Med Biol 1996; 394:279-89.
29. Berson A, Fau D, Fornacciari R, et al. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol 2001; 34:261-9.